Cardiopulmonary exercise testing revealed reduced exercise tolerance (median peak V˙O2 14.7 mL/kg/min, 63% predicted; 43% below 14 mL/kg/min threshold) in Japanese cancer patients with cardiovascular complications regardless of cardiac dysfunction status.
Observational (n=28)
No
Cardiopulmonary exercise testing reveals markedly reduced exercise tolerance in cancer patients with cardiovascular complications, which does not necessarily parallel left ventricular ejection fraction, highlighting the need for individualized cardio-oncology rehabilitation.
p-value: p=No significant difference between CTRCD and non-CTRCD groups in CPX parameters
Background: Despite growing interest in cardio-oncology rehabilitation (CORE), data on cardiopulmonary exercise testing (CPX/CPET) in Japanese cancer patients remain scarce.
Saijo et al. (Wed,) conducted a observational in Japanese adult cancer patients (median age 60, 68% female) with active cancer undergoing or post-chemotherapy and concurrent cardiovascular problems including cancer therapy-related cardiac dysfunction (CTRCD) and other cardiac conditions. (n=28). Cardiopulmonary exercise testing (CPX) was evaluated on Exercise tolerance measured by peak oxygen uptake (peak V˙O2), anaerobic threshold (AT), ventilatory efficiency (V˙E vs. V˙CO2 slope), and metabolic equivalents (METs) (p=No significant difference between CTRCD and non-CTRCD groups in CPX parameters). Cardiopulmonary exercise testing revealed reduced exercise tolerance (median peak V˙O2 14.7 mL/kg/min, 63% predicted; 43% below 14 mL/kg/min threshold) in Japanese cancer patients with cardiovascular complications regardless of cardiac dysfunction status.